What is Vaxcyte, Inc.'s operating lease liabilities?

Vaxcyte, Inc. (PCVX) reported operating lease liabilities of -$1.29M in Q1 2026.

How has Vaxcyte, Inc.'s operating lease liabilities changed year-over-year?

Vaxcyte, Inc.'s operating lease liabilities decreased by 108.0% year-over-year, from $16M to -$1.29M.

What is the long-term trend for Vaxcyte, Inc.'s operating lease liabilities?

Over 2 years (2022 to 2024), Vaxcyte, Inc.'s operating lease liabilities has grown at a 503.2% compound annual growth rate (CAGR), from $1.15M to $41.89M.

Vaxcyte, Inc. PCVX Operating lease liabilities

Operating lease liabilities at other companies

ModernaMRNA

——

Other financials

Income statement

See full

Operating income-$345.9M-91.3%

Net income-$320.6M-128%

EPS (diluted)-$2.30-121%

Balance sheet

See full

Cash & equivalents$262.3M-24.7%

Total debt$116.3M+33.5%

Total equity$3.0B-6.4%

Total assets$3.3B-0.9%

Cash flow

See full

Operating cash flow-$280.6M-68.8%

CapEx$2.1M-61.2%

Free cash flow-$282.7M-64.7%

Valuation

See full

Market cap$7.43B+72.0%

Enterprise value$7.28B+78.6%

Returns & leverage

See full

Return on equity-30.6%+37.9pp

Debt / equity0×0.0×

Current ratio7.5×-10.2×

Where this comes from

Reported directly by Vaxcyte, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.

The official record: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vaxcyte, Inc.'s operating lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Vaxcyte, Inc.'s operating lease liabilities?: Vaxcyte, Inc. (PCVX) reported operating lease liabilities of -$1.29M in Q1 2026.
How has Vaxcyte, Inc.'s operating lease liabilities changed year-over-year?: Vaxcyte, Inc.'s operating lease liabilities decreased by 108.0% year-over-year, from $16M to -$1.29M.
What is the long-term trend for Vaxcyte, Inc.'s operating lease liabilities?: Over 2 years (2022 to 2024), Vaxcyte, Inc.'s operating lease liabilities has grown at a 503.2% compound annual growth rate (CAGR), from $1.15M to $41.89M.